vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Howard Hughes Holdings Inc. (HHH). Click either name above to swap in a different company.
Howard Hughes Holdings Inc. is the larger business by last-quarter revenue ($235.9M vs $180.9M, roughly 1.3× AVANOS MEDICAL, INC.). Howard Hughes Holdings Inc. runs the higher net margin — 3.4% vs -0.7%, a 4.1% gap on every dollar of revenue. On growth, Howard Hughes Holdings Inc. posted the faster year-over-year revenue change (18.4% vs 0.7%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -13.8%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Howard Hughes Holdings Inc., formerly the Howard Hughes Corporation, is a real estate development and management company based in The Woodlands, Texas. It was formed in 2010 as a spin-off from General Growth Properties (GGP). Most of its holdings are focused on several master-planned communities. It took its name from the original Howard Hughes Corporation, which had developed the planned community of Summerlin, Nevada, and later became a subsidiary of GGP.
AVNS vs HHH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $235.9M |
| Net Profit | $-1.3M | $8.1M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 121.6% |
| Net Margin | -0.7% | 3.4% |
| Revenue YoY | 0.7% | 18.4% |
| Net Profit YoY | 99.7% | -25.6% |
| EPS (diluted) | $-0.02 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $235.9M | ||
| Q4 25 | $180.9M | $624.4M | ||
| Q3 25 | $177.8M | $390.2M | ||
| Q2 25 | $175.0M | $260.9M | ||
| Q1 25 | $167.5M | $199.3M | ||
| Q4 24 | $179.6M | $935.0M | ||
| Q3 24 | $170.4M | $327.1M | ||
| Q2 24 | $171.7M | $317.4M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $-1.3M | $6.0M | ||
| Q3 25 | $-1.4M | $119.5M | ||
| Q2 25 | $-76.8M | $-12.1M | ||
| Q1 25 | $6.6M | $10.5M | ||
| Q4 24 | $-397.3M | $156.3M | ||
| Q3 24 | $4.3M | $72.8M | ||
| Q2 24 | $1.8M | $21.1M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | 121.6% | ||
| Q4 25 | 1.4% | 4.2% | ||
| Q3 25 | 0.1% | 48.6% | ||
| Q2 25 | -42.6% | 26.0% | ||
| Q1 25 | 6.1% | 24.0% | ||
| Q4 24 | -233.0% | 33.5% | ||
| Q3 24 | 7.0% | 60.6% | ||
| Q2 24 | 3.7% | 20.4% |
| Q1 26 | — | 3.4% | ||
| Q4 25 | -0.7% | 1.0% | ||
| Q3 25 | -0.8% | 30.6% | ||
| Q2 25 | -43.9% | -4.7% | ||
| Q1 25 | 3.9% | 5.3% | ||
| Q4 24 | -221.2% | 16.7% | ||
| Q3 24 | 2.5% | 22.2% | ||
| Q2 24 | 1.0% | 6.6% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $-0.02 | $0.20 | ||
| Q3 25 | $-0.03 | $2.02 | ||
| Q2 25 | $-1.66 | $-0.22 | ||
| Q1 25 | $0.14 | $0.21 | ||
| Q4 24 | $-8.64 | $3.14 | ||
| Q3 24 | $0.09 | $1.46 | ||
| Q2 24 | $0.04 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $1.8B |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $3.8B |
| Total Assets | $1.1B | $11.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $89.8M | $1.5B | ||
| Q3 25 | $70.5M | $1.5B | ||
| Q2 25 | $90.3M | $1.4B | ||
| Q1 25 | $97.0M | $493.7M | ||
| Q4 24 | $107.7M | $596.1M | ||
| Q3 24 | $89.0M | $400.7M | ||
| Q2 24 | $92.2M | $436.8M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | $5.1B | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $5.1B | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | $3.8B | ||
| Q4 25 | $778.2M | $3.8B | ||
| Q3 25 | $778.0M | $3.8B | ||
| Q2 25 | $776.3M | $3.6B | ||
| Q1 25 | $839.4M | $2.8B | ||
| Q4 24 | $828.5M | $2.8B | ||
| Q3 24 | $1.2B | $2.6B | ||
| Q2 24 | $1.2B | $3.0B |
| Q1 26 | — | $11.2B | ||
| Q4 25 | $1.1B | $10.6B | ||
| Q3 25 | $1.1B | $10.7B | ||
| Q2 25 | $1.0B | $10.3B | ||
| Q1 25 | $1.1B | $9.3B | ||
| Q4 24 | $1.2B | $9.2B | ||
| Q3 24 | $1.7B | $9.4B | ||
| Q2 24 | $1.7B | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | 1.35× | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 1.85× | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $360.3M | ||
| Q3 25 | $14.0M | $149.8M | ||
| Q2 25 | $6.8M | $177.3M | ||
| Q1 25 | $25.7M | $-224.9M | ||
| Q4 24 | $57.9M | $337.1M | ||
| Q3 24 | $23.0M | $248.3M | ||
| Q2 24 | $27.8M | $-17.5M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $348.6M | ||
| Q3 25 | $7.0M | $137.7M | ||
| Q2 25 | $-4.2M | $169.7M | ||
| Q1 25 | $19.0M | $-238.4M | ||
| Q4 24 | $53.1M | $317.1M | ||
| Q3 24 | $20.0M | $238.7M | ||
| Q2 24 | $21.9M | $-25.1M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 55.8% | ||
| Q3 25 | 3.9% | 35.3% | ||
| Q2 25 | -2.4% | 65.1% | ||
| Q1 25 | 11.3% | -119.6% | ||
| Q4 24 | 29.6% | 33.9% | ||
| Q3 24 | 11.7% | 73.0% | ||
| Q2 24 | 12.8% | -7.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 1.9% | ||
| Q3 25 | 3.9% | 3.1% | ||
| Q2 25 | 6.3% | 2.9% | ||
| Q1 25 | 4.0% | 6.8% | ||
| Q4 24 | 2.7% | 2.1% | ||
| Q3 24 | 1.8% | 2.9% | ||
| Q2 24 | 3.4% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 60.04× | ||
| Q3 25 | — | 1.25× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | -21.35× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | 5.35× | 3.41× | ||
| Q2 24 | 15.44× | -0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
HHH
| Rental revenue | $113.5M | 48% |
| Master Planned Communities land sales | $99.6M | 42% |
| Other revenues | $11.0M | 5% |
| Builder price participation | $8.7M | 4% |
| Condominium rights and unit sales | $3.1M | 1% |
